CYP3A4 and infection: Among the cohort, 14 (33.3%) patients had infection before induction therapy, 6 (14.3%) received CYP3A4 inhibitors (4 voriconazole and 2 posaconazole) during Ven induction therapy, and 3 (7.14%) were administered oral Ven (200 mg) on Day 1.